Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07019662

Comparing a Suture-based System for the Removal of Arterial and Veinous ECMO Cannulas to the Standard Approach

Background:

Patients with severe heart and lung failure may be treated with VA-ECMO (veno-arterial extracorporeal membrane oxygenation), a life-support machine that temporarily takes over the function of the heart and lungs. To connect the patient to ECMO, large tubes (cannulas) are inserted into major blood vessels in the groin area.

When the patient no longer needs ECMO, these cannulas must be removed - a process known as decannulation. Closing the artery after removing the cannula is a critical step and can be associated with complications such as bleeding, vessel injury, or blood clots.

Currently, there are different methods to close the artery:

* Surgical closure: open surgery to directly suture the artery * Manual compression: pressing on the artery to stop bleeding * Vascular closure devices (VCDs): special tools that close the artery through the skin

There is no clear standard yet on which method is safest and most effective for ECMO patients.

Purpose of the Study:

The study aims to determine whether using a vascular closure device is as safe and effective as the current standard methods for femoral artery closure after VA-ECMO.

Study Design:

This is a randomized controlled trial. Patients who are scheduled for decannulation after VA-ECMO support will be randomly assigned to one of two groups:

* Intervention Group: Patients receive a vascular closure device to seal the artery (Abbott Perclose™ ProStyle™ Suture-Mediated Closure System). * Control Group: Patients receive standard care, which may be either:

* Manual compression, or * Surgical closure, depending on the treating physician's judgment and the patient's condition.

This allows for a real-world comparison of the Closure Device method to current clinical practice.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Universitäres Herz- und Gefäßzentrum Frankfurt ZIM - Med. Clinic 3 - Cardiology and Angiology, Frankfurt, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 Years
  • Femoral placement of VA-ECMO with peripheral, percutaneous cannulation
  • Arterial puncture site above the femoral bifurcation
  • Cannula size must match or be smaller than the maximally licensed diameter for Perclose™ ProStyle™ (26 F (French) outer diameter arterial and 29 F outer diameter veinous)
  • Patients must be eligible for either the Perclose™ ProStyle™ device or one of the two guideline-compliant alternatives for ECMO cannula removal (manual compression or surgical closure) according to the investigator's judgment.
  • Initial arterial and/or venous puncture for ECMO cannulation was performed using ultrasound guidance with corresponding documentation available in the patient record.

Exclusion criteria

  • Severe calcification
  • Surgical cannulation
  • Ongoing Infection of the ECMO site
  • Any patient who does not fullfil the eligibility criteria for the use of the study device according to its current Instructions for Use (IFU), including known contraindications, limitations or warnings.
  • Participation in another interventional clinical trial.
  • Patients who are pregnant (assessed by clinical routine testing) or lactating.

Treatment and study plan

Decannulation with a medical device

Device

Wound Closure with a medical device

Decannulation using surgical removal or manual compression

Procedure

Wound closure using surgical removal or manual compression

Primary outcomes

  1. Incidence of a combined vessel-orientated clinical endpoint (VOCE)

    Time frame: within 48 hours post ECMO removal

Secondary outcomes

  1. Length of ICU (intensive care unit) stay post ECMO removal

    Time frame: Prior to hospital discharge, but no longer than 30 days after ECMO decannulation, whichever occurs first

  2. Length of hospital stay post ECMO removal

    Time frame: Prior to hospital discharge, but no longer than 30 days after ECMO decannulation, whichever occurs first

  3. Time to mobilization post ECMO removal

    Time frame: Prior to hospital discharge, but no longer than 30 days after ECMO decannulation, whichever occurs first

  4. Costs of hospital stay

    Time frame: Prior to hospital discharge, but no longer than 30 days after ECMO decannulation, whichever occurs first

  5. Incidence of Bleeding requiring transfusion (BARC3a)

    Time frame: At 48 hours post-ECMO and prior to hospital discharge, but no longer than 30 days after ECMO decannulation, whichever occurs first

  6. Vascular complication requiring surgical or interventional therapy

    Time frame: At 48 hours post-ECMO and prior to hospital discharge, but no longer than 30 days after ECMO decannulation, whichever occurs first

  7. Wound infection requiring antibiotic use or surgical debridement

    Time frame: At 48 hours post-ECMO and prior to hospital discharge, but no longer than 30 days after ECMO decannulation, whichever occurs first

  8. Rate of pseudoaneurysms as detected by vascular Ultrasound

    Time frame: At 48 hours post-ECMO and prior to hospital discharge, but no longer than 30 days after ECMO decannulation, whichever occurs first

  9. Rate of veinous thrombosis in the lower vessels as detected by vascular ultrasound

    Time frame: At 48 hours post-ECMO and prior to hospital discharge, but no longer than 30 days after ECMO decannulation, whichever occurs first

  10. Rate of arterial thrombosis in the lower vessel as detected by vascular ultrasound

    Time frame: At 48 hours post-ECMO and prior to hospital discharge, but no longer than 30 days after ECMO decannulation, whichever occurs first

Study contacts

Contact information is provided by the study sponsor or research team.

Jelena Weller

CONTACT

[email protected]

+49 62159577216

Marcel Kunadt, Dr.

CONTACT

Sponsors and collaborators

Lead sponsor

IHF GmbH - Institut für Herzinfarktforschung

Other

Registry information

Acronym: CLOSE-ECMO

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Jun 13, 2025
Registry last updated
Apr 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.